?? ?Levodropropizine (CAS 99291-25-5) - Product Overview?
Levodropropizine is a ?peripherally acting antitussive agent? (molecular formula: ?C??H??N?O??, MW: 236.31) designed to treat ?acute dry cough? caused by upper respiratory infections and bronchitis. As the ?S-enantiomer of dropropizine?, it selectively inhibits sensory nerve endings in the airways, reducing cough reflex activation with minimal central side effects. This white crystalline powder (HPLC purity ≥99%) exhibits excellent stability under ?room temperature storage?, ideal for oral solid and liquid formulations?12.

?? ?Key Advantages?
?? ?High Efficacy?: Reduces cough frequency by ?>50%? within 2 hours post-administration?13.
?? ?Rapid Action?: Achieves peak plasma concentration in ?1-1.5 hours? for quick symptom relief?12.
?? ?Safety Profile?: Low sedation risk (incidence <2%) compared to codeine-based antitussives?13.
?? ?Solubility?: Water solubility ≥20 mg/mL for flexible formulation development?47.

?? ?Applications?

1. ?Cough Suppressants?: First-line treatment for acute non-productive cough in adults and children?.

2. ?Pediatric Formulations?: Used in syrups and oral drops due to favorable tolerability?.

3. ?Research?: Tool for studying peripheral cough reflex mechanisms and enantiomer-specific drug effects?.

?? ?Quality Certifications?

• Complies with ?USP/EP? pharmacopeial standards for API purity?.

• Rigorously tested via ?HPLC (≥99%)?, ?GC?, and ?FTIR? for structural validation?.

• Manufactured in ?GMP?-certified facilities with ISO 9001 compliance?.

?? ?Market Insights?
The global antitussive drug market is projected to grow at ?5.8% CAGR through 2030?, driven by rising respiratory infections. Levodropropizine holds ?>15% market share? in non-opioid cough suppressants, favored for its enantiomeric purity and pediatric safety?.